Drug Trial Radar · NCT05171062
Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jul 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jun 2023
Primary completion
Dec 2025
Study completion Dec 2026
Sponsor
- Lead sponsor
- The University of Texas Health Science Center at San AntonioAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Faron Pharmaceuticals Ltd
- First posted
- Dec 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study enrolls patients with Non-small cell lung cancer and treats them with the investigational drug Bexmarilimab (FP-1305) plus standard of care Pembrolizumab to block Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1). Treating with an antiCLEVER-1 antibody, such as bexmarilimab, could lead to immune system activation, which, in turn, may lead to cancer elimination.
Conditions
- Non-small Cell Lung Cancer
Interventions
bexmarilimab (FP-1305)Drug
standard 3+3 dose escalation trial of bexmarilimab (FP-1305)
PembrolizumabDrug
Pembrolizumab 200mg IV is administered in 4 planned bexmarilimab dose escalation cohorts
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: Cycle 2 plus 3 weeks (21 days following the first dose of both study drugs)
- Programmed Death Cell Ligand 1 (PD-L1) levelTime frame: Cycle 1 (21 days), pre-dose levels at start of Cycle 3 (42 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mays Cancer Center, UT Health San Antonio
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.